Pharmazeutische Zusammensetzungen von 2-(3,5-Dichlorphenyl)-1,3-Benzoxazol-6-Carbonsäure
EP4717262
1. April 2026
Anmelder: Galenicum Health S.L.U. 🇪🇸
Details
- Veröffentlichungs-Nr.
- EP4717262
- Anmeldetag
- 23. September 2025
- Veröffentlichung
- 1. April 2026
- Rechtsraum
- EP
- IPC
- (SHANMUGAM MUTHUSAMY et al.)
Abstract
The present invention provides pharmaceutical compositions comprising tafamidis free acid as the active pharmaceutical ingredient and pharmaceutical dosage forms containing such compositions. These formulations are intended for the treatment and prevention of polyneuropathies, particularly familial amyloid polyneuropathy (FAP) and transthyretin amyloid polyneuropathy (ATTR-PN). The invention also includes processes for the preparation of these dosage forms and methods of treating patients in need of such therapies.
Anmelder
- Firma
- Galenicum Health S.L.U.
- Land
- 🇪🇸 Spanien
Vertreten von
-
Galenicum Health S.L.U
Galenicum Health S.L.U · Esplugues de Llobregat